Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 18/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.44 |
| ▸ | PTGFR | P43088 | 1/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15249969 | 0.93 | PTGER4 (0.87) | PTGER4PTGER2LMNANPSR1SMN1; SMN2 | |
| SCHEMBL10122404 | 0.92 | PTGER4 (1.00) | PTGER4PTGER2SMN1; SMN2 | |
| SCHEMBL15249882 | 0.91 | PTGER4 (0.83) | PTGER4PTGER2LMNANPSR1TBXA2R | |
| SCHEMBL881216 | 0.90 | PTGER4 (0.81) | PTGER4PTGER2TBXA2RPTGER1PTGFR | |
| SCHEMBL10122400 | 0.89 | PTGER4 (1.00) | PTGER4PTGER2SMN1; SMN2 | |
| SCHEMBL881197 | 0.86 | PTGER4 (0.76) | PTGER4PTGER2LMNANPSR1TBXA2R | |
| SCHEMBL24861752 | 0.86 | PTGER4 (0.94) | PTGER4PTGER2SMN1; SMN2 | |
| SCHEMBL881504 | 0.85 | PTGER4 (0.74) | PTGER4PTGER2LMNANPSR1TBXA2R | |
| SCHEMBL881421 | 0.85 | PTGER4 (0.74) | PTGER4PTGER2LMNANPSR1TBXA2R | |
| SCHEMBL15249963 | 0.85 | PTGER4 (0.87) | PTGER4PTGER2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707448-B2 | Combination therapies for the treatment of cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-07-25 | — | — | US | disclosed |
| US-20170182003-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-06-29 | — | — | US | disclosed |
| EP-2619182-B1 | PHARMACEUTICAL COMPOSITION | EISAI R&D MAN CO LTD (JP) | 2016-11-09 | — | — | EP | disclosed |
| EP-3061751-A1 | PHARMACEUTICAL COMPOSITION | Eisai R&D Management Co., Ltd. (JP) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015179615-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | EISAI R&D MANAGEMENT CO., LTD (JP) | 2015-11-26 | — | — | WO | disclosed |
| US-9000024-B2 | Pharmaceutical composition | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-9000024-B2 | Pharmaceutical composition | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20140155452-A1 | PHARMACEUTICAL COMPOSITION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-05 | — | — | US | disclosed |
| US-20140155452-A1 | PHARMACEUTICAL COMPOSITION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-05 | — | — | US | disclosed |
| US-20130237578-A1 | PHARMACEUTICAL COMPOSITION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-09-12 | — | — | US | disclosed |
| US-20130237578-A1 | PHARMACEUTICAL COMPOSITION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-09-12 | — | — | US | disclosed |
| WO-2012039972-A1 | PHARMACEUTICAL COMPOSITION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182003-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885LMNA 3618/4885 |
| US-11707448-B2 | Combination therapies for the treatment of cancer | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885LMNA 3618/4885 |
| US-20140155452-A1 | PHARMACEUTICAL COMPOSITION | CYP3A5, CYP2C19, CYP3A7 | PTGER4 147/4885PTGER2 131/4885LMNA 2386/4885 |
| US-20130237578-A1 | PHARMACEUTICAL COMPOSITION | CYP3A5, CYP2C19, CYP3A7 | PTGER4 147/4885PTGER2 131/4885LMNA 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.